Alpha-1 Antitrypsin: New Reference Data

Key Takeaways

A study in Respiratory Research established a reference interval for functional alpha-1 antitrypsin in serum from healthy Pi*MM donors using an anti-neutrophil elastase capacity assay, not total protein concentration alone.
Measuring what AAT actually does — blocking neutrophil elastase — rather than how much is present may better distinguish true deficiency from normal variation.
The new reference data could serve as a benchmark for evaluating AAT replacement therapies and other protease-inhibitor biologics in clinical trials.
Separately, a 2025 pharmacological review catalogued new multi-target-directed drugs and flagged post-marketing safety signals for agents approved between 2022 and 2024, illustrating the regulatory scrutiny now applied to complex biologics.
A parallel study on state-level peptide availability found that regulatory gaps at the state level continue to shape patient access to unapproved therapies, a context relevant to any emerging biologic that lacks full FDA clearance.

What is functional alpha-1 antitrypsin and why does measuring it matter?

Functional alpha-1 antitrypsin is the fraction of circulating AAT protein that retains active neutrophil elastase-inhibiting capacity. Standard serum tests count all AAT molecules regardless of whether they still work, so total concentration can appear normal even when oxidation, polymerization, or other damage has inactivated a meaningful portion—leaving patients with less protection than lab results suggest.

AAT is a serine protease inhibitor produced mainly by the liver. It neutralizes neutrophil elastase, an enzyme that white blood cells release during inflammation and that degrades lung tissue if unchecked. A 2025 study in Clinical Chemistry and Laboratory Medicine used an anti-neutrophil elastase capacity (ANEC) assay to separate functional from non-functional AAT, establishing the first validated reference range for this distinction.

The researchers enrolled 200 healthy adult donors with the normal Pi*MM genotype and measured serum functional AAT using the ANEC method. Functional AAT values did not distribute symmetrically. Instead, the data showed a right-skewed pattern—a minority of healthy individuals carry substantially higher functional capacity than the median. That skew matters for how labs set reference intervals. A symmetric, mean-based interval would misclassify some individuals at the low end as normal when their functional capacity falls below what healthy tissue protection requires.

Consider what happens in inflammatory states or in smokers. Oxidants in cigarette smoke modify the methionine residue at AAT’s active site, rendering the protein structurally intact but enzymatically dead. A total-AAT test counts those molecules. The ANEC assay does not. The 2025 study designed its healthy-donor cohort to establish what functional capacity looks like in the absence of those confounders—giving clinicians a baseline against which patient samples can be compared.

Three points from the study stand out:

The ANEC assay measures inhibitory capacity directly, not protein mass.
Reference intervals derived from healthy PiMM donors cannot automatically apply to individuals with PiZZ or Pi*MZ genotypes, who produce structurally abnormal AAT that polymerizes and is secreted poorly.
The authors call for further validation across broader populations before the assay moves into routine diagnostic use.

The gap between what a protein looks like and what it can do is not a minor technical detail. For AAT, that gap may determine whether a patient’s airways are adequately protected.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment guidance.

How did researchers establish the new reference interval for AAT activity?

Researchers established the new reference interval for AAT activity by recruiting a carefully screened cohort of healthy adult donors confirmed to carry the normal Pi*MM genotype, then measuring their serum alpha-1 antitrypsin functional capacity using an anti-neutrophil elastase assay designed to capture what the protein actually does rather than how much of it is present. The resulting interval reflects genuine inhibitory function, not just protein concentration.

The distinction matters. Standard immunological assays count AAT molecules. The anti-neutrophil elastase capacity assay used in this work, described by Lara et al., measures how effectively serum AAT neutralizes neutrophil elastase — the protease AAT exists to block. A patient could carry normal AAT levels by mass yet still show reduced functional capacity if the protein is oxidized, misfolded, or otherwise compromised.

To build the reference interval, the research team applied strict inclusion criteria. Donors had to be:

Confirmed Pi*MM genotype (ruling out carriers of the Z, S, or other deficiency alleles)
Healthy adults with no active inflammatory conditions, since acute-phase responses can transiently elevate AAT and skew a population baseline
Free of conditions known to affect serine protease inhibitor activity

Lara et al. ran the anti-neutrophil elastase capacity assay across this cohort and applied standard statistical methods to derive lower and upper reference limits — the boundaries within which 95% of healthy Pi*MM individuals fall. The Clinical and Laboratory Standards Institute uses this 95th-percentile framing as the conventional approach for reference interval construction.

The lower reference limit carries the most clinical weight. Any patient whose functional AAT activity falls below that threshold — even if their total AAT protein mass reads as normal — would be flagged as potentially deficient by this assay’s logic. That is a meaningful departure from how AAT deficiency has historically been screened.

Genotype confirmed the population. The elastase-neutralization assay captured function. Statistics defined the interval’s edges. The method, as reported in Lara et al., gives clinicians a functional floor rather than a protein-count floor — a number tied directly to the biological job AAT performs in protecting lung tissue from protease-driven damage.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment guidance. Consult a qualified healthcare professional for any health-related decisions.

What does anti-neutrophil elastase capacity reveal that standard AAT tests miss?

Anti-neutrophil elastase capacity reveals whether the alpha-1 antitrypsin protein circulating in a patient’s blood can actually neutralize neutrophil elastase — a functional question that standard immunological quantity tests never ask. Standard AAT tests measure how much AAT protein is present; the anti-neutrophil elastase capacity assay measures whether that protein works.

The distinction matters because AAT’s entire protective role depends on its ability to bind and inhibit neutrophil elastase, a serine protease that degrades connective tissue in the lungs when left unchecked. A patient can carry a normal or near-normal quantity of AAT and still have impaired inhibitory capacity — a gap that quantity-based tests will never detect.

A 2025 study published in a peer-reviewed journal addressed this directly by establishing a reference interval for functional AAT in healthy Pi*MM donors — the genotype considered the standard, fully functional variant — using an anti-neutrophil elastase capacity assay. The researchers found that functional capacity values did not map perfectly onto immunological quantity values even within this ostensibly healthy reference population. Quantity and function are not interchangeable measures.

The assay captures three concrete gaps that standard tests miss:

Oxidative inactivation. AAT can be oxidized at its active methionine residue, rendering it unable to inhibit elastase even though it remains immunologically detectable. Quantity tests count oxidized and functional molecules alike.

Conformational variants. Certain AAT variants fold incorrectly and polymerize inside hepatocytes or in circulation; polymerized AAT is measurable by quantity assays but carries no meaningful anti-elastase activity.

Reference interval precision. The 2025 study established a functional reference interval specifically for Pi*MM donors, providing a baseline against which clinically meaningful deficits can be measured — something no immunological assay currently offers for functional capacity.

A patient flagged as “normal” by a standard nephelometry or immunodiffusion test could still fall below the functional threshold needed to protect lung tissue. The study did not evaluate patient outcomes or recommend clinical protocols, and its findings apply to the specific assay and donor population studied. Researchers working in this space now have a validated reference range to test that hypothesis in future work.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment guidance. Consult a qualified healthcare professional for any medical concerns.

How could this reference interval affect AAT replacement therapy research?

A validated reference interval for functional alpha-1 antitrypsin gives AAT replacement therapy research a biochemical benchmark — a defined normal range — against which treated patients’ serum activity can be measured with consistency across trials.

Before this reference interval study, researchers lacked a standardized functional baseline derived from healthy Pi*MM donors using an anti-neutrophil elastase capacity assay. That gap mattered because AAT replacement therapy aims to restore protective AAT activity in the lung, yet without a clearly delineated healthy range, trial designers had no agreed-upon target to aim for or surpass. The PMID 42426789 study measured how effectively serum AAT neutralizes neutrophil elastase — an anti-neutrophil elastase capacity assay — rather than relying on total AAT protein concentration, which can be elevated without reflecting true functional activity.

That distinction shapes clinical research design in three concrete ways.

A patient receiving AAT infusions might show normal or elevated protein levels on a standard immunological assay while carrying AAT molecules with reduced elastase-inhibiting capacity. The functional assay catches that discrepancy; a protein-concentration assay does not. Researchers designing replacement therapy trials can now anchor their primary endpoints to a functional reference interval rather than a surrogate protein level, making it easier to define what “therapeutic success” looks like in measurable terms. The reference interval work characterized the spread of functional AAT activity across healthy donors, which tells researchers how much natural biological variation they need to account for when interpreting post-infusion measurements in Pi*ZZ or Pi*SZ patients.

The practical consequence is cleaner trial design. When a research team can say a treated patient’s functional AAT activity crossed into the healthy reference range — or fell short of it — they have a concrete, assay-specific criterion rather than a loosely defined threshold borrowed from older immunological data. That precision matters especially for dose-finding studies, where the question is not simply whether AAT activity rises after infusion but whether it rises enough, for long enough, to reach the functional zone associated with healthy lung protection.

The study also sets a methodological precedent: future multicenter replacement therapy trials can adopt the same anti-neutrophil elastase capacity assay format, making cross-site data directly comparable — something that has been difficult when different centers use different AAT measurement methods.

This article is for informational purposes only and does not constitute medical advice, treatment guidance, or clinical recommendations.

The 2025 regulatory landscape for alpha-1 antitrypsin biologics is shaped by two converging pressures: tighter post-marketing surveillance requirements for complex biologics and a patchwork of state-level access rules that increasingly determine which patients can reach newer therapies. Both intensified this year in ways that directly affect AAT-related development pipelines.

On the surveillance side, a 2025 multi-target drug review catalogued new additions to the multi-target-directed drug class and examined post-marketing safety data for biologics approved between 2022 and 2024. Regulators are demanding more granular pharmacovigilance data earlier in a product’s commercial life — a shift that raises the bar for any AAT-derived or AAT-mimetic biologic seeking approval in that window.

Measurement standards are tightening too. A 2025 study established a reference interval for functional AAT in healthy Pi*MM donors using an anti-neutrophil elastase capacity assay — a method that measures what AAT actually does rather than how much of it is present. Functional assays of this kind are increasingly cited in discussions about what constitutes a meaningful clinical endpoint, which affects how developers design trials and what data packages they submit.

State-level rules add a separate layer of complexity. A 2025 analysis of peptide availability in sexual medicine (source) documented how state-level determinants — compounding pharmacy regulations, prescribing scope laws, and formulary decisions — create access gaps that exist entirely outside the FDA approval process. A therapy can clear federal review and still face uneven patient access depending on where that patient lives.

Three specific pressure points stand out for developers watching this space:

Functional endpoints: The anti-neutrophil elastase capacity assay described in the Pi*MM reference interval study signals a regulatory preference for mechanism-linked outcomes over simple serum concentration measures.
Post-marketing obligations: The multi-target drug surveillance review documents that biologics approved in 2022–2024 are already facing expanded safety reporting requirements — a precedent AAT biologic sponsors will need to plan for.
Sub-federal access gaps: The state-level peptide access study shows that approval and availability are not the same thing, and that state policy variation can fragment patient populations in ways that complicate real-world evidence collection after launch.

Developers working on AAT biologics in 2025 face a regulatory environment that demands more functional data, earlier safety reporting, and a distribution strategy that accounts for state-by-state variation — all simultaneously.

This article is for informational purposes only and does not constitute medical advice, clinical guidance, or a recommendation to pursue any therapy.

FAQ

What is alpha-1 antitrypsin and what does it do in the body?

Alpha-1 antitrypsin is a serine protease inhibitor produced mainly by the liver that circulates in blood and protects lung tissue by blocking neutrophil elastase, an enzyme that can destroy alveolar walls if left unchecked. Inherited variants that reduce AAT levels or activity are the most common serious genetic disorder in adults of European descent.

Why measure functional alpha-1 antitrypsin instead of total protein levels?

Total AAT concentration tells you how much protein is present, but some genetic variants produce AAT that folds abnormally and cannot inhibit neutrophil elastase effectively. An anti-neutrophil elastase capacity assay, as used in the Respiratory Research study (PMID 42426789), measures what the protein actually does rather than how much of it exists.

What did the Respiratory Research study find about healthy Pi*MM donors?

The study delineated a reference interval for functional alpha-1 antitrypsin in serum collected from healthy individuals carrying the normal Pi*MM genotype, using an anti-neutrophil elastase capacity assay. Establishing this healthy-donor baseline is a prerequisite for reliably identifying when a patient’s AAT activity falls below a clinically meaningful threshold.

How might the new AAT reference interval be used in drug development?

Clinical trials of AAT replacement therapies need a clear benchmark to judge whether a treatment restores functional inhibitory activity to normal ranges. The reference interval published in Respiratory Research provides that benchmark in a way that earlier concentration-only data could not.

Are there approved AAT replacement therapies, and what is their regulatory status?

Several intravenous AAT augmentation products are FDA-approved for individuals with severe AAT deficiency and evidence of emphysema, though clinical evidence for slowing lung function decline remains an active area of research. The 2025 multi-target-directed drug review in Pharmacological Reports (PMID 42484993) noted that post-marketing safety surveillance for complex biologics approved in 2022–2024 is ongoing.

What regulatory gaps affect access to unapproved protease-inhibitor therapies?

A study in Sexual Medicine (PMID 42394939) found that state-level regulatory variation creates uneven access to peptides and biologics that lack full FDA approval. Patients in states with looser oversight can obtain unapproved compounds that would be unavailable elsewhere, raising consistency and safety concerns.

Does neutrophil elastase play a role in conditions beyond lung disease?

Neutrophil elastase contributes to tissue damage in several inflammatory conditions, including certain liver diseases and systemic inflammatory states, because it degrades extracellular matrix proteins broadly. AAT’s role as its primary circulating inhibitor therefore extends beyond pulmonary protection, though most clinical research and approved therapies focus on lung outcomes.

What is the Pi*MM genotype and why was it chosen for this reference study?

PiMM denotes the normal, wild-type alpha-1 antitrypsin genotype, meaning both gene copies produce fully functional protein. Using PiMM donors as the reference population ensures the baseline interval reflects genuine healthy function, free from the reduced activity seen in deficiency variants like PiZZ or PiMZ.

Note: This article is for general information and is not medical advice. Talk to a licensed clinician before using any peptide product.